Halozyme
HALO · Biotechnology
$125.63
0.9%Repligen
RGEN · Biotechnology
$176.93
1.0%The short version
- Halozyme is the larger business, with $1.4B of revenue in fiscal 2025 against $738M for Repligen, about 1.9 times as much.
- Halozyme grew revenue faster (37.6%, against 16.4%).
- Halozyme kept more of each dollar of sales as operating profit (33.6% operating margin, against 7.5% operating margin).
- Halozyme turned more of its sales into free cash flow (46.2% FCF margin, against 12.7% FCF margin).
- Halozyme earned a higher return on the capital invested in it (19.2%, against 2.4%).
| Latest fiscal year | HALO · FY25 | RGEN · FY25 |
|---|---|---|
| Size | ||
| Market cap | $15.2B | — |
| Revenue | $1.4B | $738M |
| Free cash flow | $645M | $93.9M |
| Net income | $317M | $48.9M |
| Growth | ||
| Revenue growth | 37.6% | 16.4% |
| 5-year growth | 39.2% | 15.1% |
| Share count change | −4.3% | — |
| Profitability | ||
| Gross margin | 83.6% | 52.3% |
| Operating margin | 33.6% | 7.5% |
| Net margin | 22.7% | 6.6% |
| FCF margin | 46.2% | 12.7% |
| Return on capital | 19.2% | 2.4% |
| Return on equity | 153.6% | 2.4% |
| Balance sheet | ||
| Net debt | $2.0B | −$225M |
| Net debt / EBITDA | 4.2x | −1.7x |
| Dividends and buybacks | $342M | $0.0M |
| Valuation & quality | ||
| P/E | 36.6x | — |
| Piotroski F-score | 5 | — |
FY16
HALO $147M
RGEN $105M
FY17
HALO $317M
RGEN $141M
FY18
HALO $152M
RGEN $194M
FY19
HALO $196M
RGEN $270M
FY20
HALO $268M
RGEN $366M
FY21
HALO $443M
RGEN $671M
FY22
HALO $660M
RGEN $802M
FY23
HALO $829M
RGEN $632M
FY24
HALO $1.0B
RGEN $634M
FY25
HALO $1.4B
RGEN $738M
HALO
RGEN
FY16
HALO −56.7%
RGEN 15.3%
FY17
HALO 25.6%
RGEN 9.9%
FY18
HALO −45.7%
RGEN 13.4%
FY19
HALO −34.5%
RGEN 13.4%
FY20
HALO 53.9%
RGEN 19.1%
FY21
HALO 62.2%
RGEN 24.9%
FY22
HALO 40.5%
RGEN 28.0%
FY23
HALO 40.7%
RGEN 7.5%
FY24
HALO 54.3%
RGEN −5.5%
FY25
HALO 33.6%
RGEN 7.5%
HALO
RGEN
FY16
HALO −$53.5M
RGEN $3.2M
FY17
HALO $133M
RGEN $12.0M
FY18
HALO −$54.2M
RGEN $22.1M
FY19
HALO −$89.5M
RGEN $48.7M
FY20
HALO $53.0M
RGEN $40.2M
FY21
HALO $298M
RGEN $51.9M
FY22
HALO $235M
RGEN $87.3M
FY23
HALO $373M
RGEN $77.7M
FY24
HALO $468M
RGEN $150M
FY25
HALO $645M
RGEN $93.9M
HALO
RGEN
FY16
HALO −103.0%
RGEN 15.2%
FY17
HALO 61.2%
RGEN 4.3%
FY18
HALO −28.1%
RGEN 3.9%
FY19
HALO −38.2%
RGEN 4.6%
FY20
HALO —
RGEN 7.7%
FY21
HALO —
RGEN 11.4%
FY22
HALO 27.9%
RGEN 12.4%
FY23
HALO 21.3%
RGEN 1.7%
FY24
HALO 34.9%
RGEN −1.6%
FY25
HALO 19.2%
RGEN 2.4%
HALO
RGEN
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.